THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.16]-C122 ID: TIP-MED-000392

Vitamin E (Tocopheryl Acetate)

Active Ingredient / Scientific Identity: Vitamin E • Class: Fat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidation Chain-Breaking Antioxidant (Schedule H / OTC | NLEM 2022 [Vit A])

⚖️ Compare Profile
Generic / Entity NameVitamin E (Tocopheryl Acetate) ([10.16]-C122)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassFat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidation Chain-Breaking Antioxi
Available Dosage FormsVitamin A Softgel Capsules: 25,000 IU, 50,000 IU; Oral Concentrate: 1,00,000 IU/mL. Vitamin E Softgel Capsules
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Avoid Vitamin A supplementation in chronic kidney disease / dialysis (renal clearance of retinol-binding protein is im
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Vitamin E (Tocopheryl Acetate) (TIP-MED-000392, Reference Code [10.16]-C122) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Fat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidation Chain-Breaking Antioxidant (Schedule H / OTC | NLEM 2022 [Vit A]). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [10.16] (Vitamin A (Retinol Palmitate) & Vitamin E (Tocopheryl Acetate)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.16], p. 134): Vitamin A: Aquasol A Capsules (USV — 25,000 IU / 50,000 IU), Govt Oral Vitamin A Solution (1,00,000 IU/mL). Vitamin E: Evion (P&G/Merck — 200 mg, 400 mg, 600 mg), E-Cod, Evion LC (+ L-Carnitine) — Strengths & Dosage Forms: Vitamin A Softgel Capsules: 25,000 IU, 50,000 IU; Oral Concentrate: 1,00,000 IU/mL. Vitamin E Softgel Capsules: 200 mg, 400 mg, 600 mg
Co-indexed constituent under primary monograph [10.16] (Vitamin A (Retinol Palmitate) & Vitamin E (Tocopheryl Acetate)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.16], p. 134): Vitamin A: Aquasol A Capsules (USV — 25,000 IU / 50,000 IU), Govt Oral Vitamin A Solution (1,00,000 IU/mL). Vitamin E: Evion (P&G/Merck — 200 mg, 400 mg, 600 mg), E-Cod, Evion LC (+ L-Carnitine) — Strengths & Dosage Forms: Vitamin A Softgel Capsules: 25,000 IU, 50,000 IU; Oral Concentrate: 1,00,000 IU/mL. Vitamin E Softgel Capsules: 200 mg, 400 mg, 600 mg
Dosage Forms & Available Strengths:
Vitamin A Softgel Capsules: 25,000 IU, 50,000 IU; Oral Concentrate: 1,00,000 IU/mL. Vitamin E Softgel Capsules: 200 mg, 400 mg, 600 mg
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Fat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidation Chain-Breaking Antioxidant (Schedule H / OTC | NLEM 2022 [Vit A]) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Fat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidation Chain-Breaking Antioxidant (Schedule H / OTC | NLEM 2022 [Vit A]) for Vitamin A: Xerophthalmia / Bitot's spots / night blindness, National Prophylaxis Programme against Nutritional Blindness in children (9 months to 5 years every 6m), and severe Measles in children (2 doses of Vit A on Day 1 & Day 2 reduce measles mortality by 50%!). Vitamin E: Vitamin E deficiency, biopsy-proven non-diabetic NASH (800 IU/d), nocturnal leg cramps (with L-Carnitine), and cyclical mastalgia.

4. Therapeutic Indications & Evidence-Supported Uses

  • Vitamin A: Xerophthalmia / Bitot's spots / night blindness, National Prophylaxis Programme against Nutritional Blindness in children (9 months to 5 years every 6m), and severe Measles in children (2 doses of Vit A on Day 1 & Day 2 reduce measles mortality by 50%!)
  • Vitamin E: Vitamin E deficiency, biopsy-proven non-diabetic NASH (800 IU/d), nocturnal leg cramps (with L-Carnitine), and cyclical mastalgia

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Vitamin A National Prophylaxis (Every 6 Months): Infant at 9 months: 1,00,000 IU (1 mL); Children 12 months to 5 years: 2,00,000 IU (2 mL) PO every 6 months. Acute Measles / Xerophthalmia (Day 1, Day 2, & Day 14): <6m: 50,000 IU; 6–11m: 1,00,000 IU; >=12m: 2,00,000 IU. Vitamin E (Adults): 200–400 mg PO OD–BD

Administration & Meal Timing: Take WITH or immediately after a fat-containing meal (both are fat-soluble vitamins requiring bile salts and dietary micelles for absorption) | Once Daily with Lunch or Dinner

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [10.16].
Metabolism & Biotransformation:
Renal: Avoid Vitamin A supplementation in chronic kidney disease / dialysis (renal clearance of retinol-binding protein is impaired in CKD, so extra Vit A causes bone toxicity & hypercalcaemia!). Hepatic: Contraindicated in hypervitaminosis A or severe liver disease
Elimination & Renal Adjustment:
Renal: Avoid Vitamin A supplementation in chronic kidney disease / dialysis (renal clearance of retinol-binding protein is impaired in CKD, so extra Vit A causes bone toxicity & hypercalcaemia!). Hepatic: Contraindicated in hypervitaminosis A or severe liver disease
Hepatic Impairment Considerations:
Renal: Avoid Vitamin A supplementation in chronic kidney disease / dialysis (renal clearance of retinol-binding protein is impaired in CKD, so extra Vit A causes bone toxicity & hypercalcaemia!). Hepatic: Contraindicated in hypervitaminosis A or severe liver disease

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CRITICAL TERATOGENICITY WARNING FOR HIGH-DOSE VITAMIN A: Vitamin A doses >10,000 IU/day (such as Aquasol A 25,000 or 50,000 IU capsules!) are POTENT HUMAN TERATOGENS and are STRICTLY CONTRAINDICATED in pregnancy and women of childbearing potential! Also NEVER combine Vitamin A with Oral Isotretinoin or Acitretin! High-dose Vitamin E (>400 IU/day long-term) inhibits Vitamin K-dependent clotting factors

Key Clinical Precautions: Renal: Avoid Vitamin A supplementation in chronic kidney disease / dialysis (renal clearance of retinol-binding protein is impaired in CKD, so extra Vit A causes bone toxicity & hypercalcaemia!). Hepatic: Contraindicated in hypervitaminosis A or severe liver disease

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Well tolerated at physiological doses
  • Hypervitaminosis A: Acute (bulging fontanelle in infants, severe headache/vomiting from benign intracranial hypertension [pseudotumour cerebri], peeling skin); Chronic (hepatotoxicity/cirrhosis, bone pain, teratogenicity). High-dose Vitamin E (>800–1200 mg/d): Increased bleeding tendency
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Vitamin A + Isotretinoin / Tetracyclines (Doxycycline/Minocycline) = Severe Pseudotumour Cerebri (benign intracranial hypertension with papilloedema & vision loss!); Orlistat, Cholestyramine, and Liquid Paraffin block absorption of Vitamins A & E; High-dose Vitamin E (>400 mg/d) potentiates Warfarin bleeding!

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.16].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: THREE VITAL COUNTER RULES: (1) Never give high-strength Vitamin A capsules (Aquasol A 25,000/50,000 IU) to a pregnant woman or anyone taking Isotretinoin (Isotroin) or Doxycycline for acne; (2) Every child with Measles should receive 2 doses of Vitamin A (Day 1 & Day 2); (3) Avoid high-dose Evion (>400 mg) if taking Warfarin/Acitrom
    • Meal & Clock Timing Instruction: Take WITH or immediately after a fat-containing meal (both are fat-soluble vitamins requiring bile salts and dietary micelles for absorption) (Once Daily with Lunch or Dinner)
    • Missed Dose Protocol: Take with next meal if missed
    • Geriatric Dispensing Pearl: Avoid Vitamin A supplements in older adults with CKD or osteoporosis (excess retinol increases hip fracture risk)

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Vitamin A Softgel Capsules: 25,000 IU, 50,000 IU; Oral Concentrate: 1,00,000 IU/mL. Vitamin E Softgel Capsules: 200 mg, 400 mg, 600 mg

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.